Low-dose edoxaban in patients 80 years and older with atrial fibrillation and dose-reduction criteria: randomized analysis between edoxaban 15 mg and 30 mg

1 September 2025 (14:05 - 14:15)
Organised by: Logo
Congress Presentation Part of: Management of cardiovascular disease in older adults Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology